Alexion ends Moderna mRNA pact

By Flora Southey

Alexion Pharmaceuticals says it is reducing R&D operations and terminating mRNA-focused preclinical partnerships.

The cell therapy oncology market is expected to reach $30bn by 2030. (Image: iStock)

GE acquires stem cell supplier Biosafe

By Melissa Fassbender

GE Health has acquired Biosafe in a move that it says will enable production of cell and gene therapies on an industrialized scale.

The additions come in response to a growing demand for immuno-oncology services (Image: iStock/royaltystockphoto)

CrownBio expands immuno-oncology offerings

By Melissa Fassbender

Crown Bioscience has expanded its immuno-oncology platform at its facilities in Europe, the US, and Asia to include immunophenotyping analysis.

Bristol-Myers Squibb has completed an expansion at its Devens, MA, biologics facility. (Photo: Business Wire)

BMS expands biologics facility in MA

By Melissa Fassbender

Bristol-Myers Squibb (BMS) has completed an expansion of its Devens, MA-based biologics facility to support the company’s growing biologics medicines portfolio.

Japan’s PuRec to supply mesenchymal stem cells

Japan’s PuRec to supply mesenchymal stem cells

By Wang Fangqing

Regenerative medicine developers now have a new supplier for mesenchymal stem cells (MSCs), the multipotent stromal cells derived from marrow and other tissues like muscle and dental pulp for tissue repair.


Follow us


View more


Featured Suppliers